GLP
Global Partners LP · Energy
45.00
2.55%(+1.12)
Market Closed46.10
2.44%(+1.10)
After HoursLast Updated: — ET
52W L: $39.5852W H: $56.51
$44.23
CHG-4.22 (-8.71%)
H$48.83
L$40.74
VOL788K
GLP (1h)
Global Partners LP · Energy
Dividend raises mean something right now.
Eli Lilly and Co (NYSE:LLY) is entering the US market slightly ahead of schedule with its oral GLP-1 weight-loss therapy Foundayo, a move Bank of America says could expand the obesity market without cannibalizing the company's existing Zepbound product. In a note to clients, Bank of America reiterated its Buy rating on Lilly, citing the early approval and favorable labeling of Foundayo, also known as orforglipron.
Foundayo launches on April 6 at the same price as Novo's pill, threatening to reshape the $50 billion obesity drug market before Novo's first-quarter results Eli Lilly and Co (NYSE:LLY) has won FDA approval for Foundayo, its oral GLP-1 weight-loss drug, with a commercial launch set for April 6. The approval, which Citi flagged as a must-read development for Novo Nordisk (NYSE:NVO) investors, arrives at one of the most difficult moments in Danish drugs giants recent history and opens a new front in the battle for the obesity market.
Oral Wegovy demonstrated "significantly greater mean weight loss" than Lilly's rival pill Foundayo, which was approved this week, Novo Nordisk said Thursday. Novo's findings evaluated previously published studies of the medicines and did not include any fresh data points.
Topline safety and pharmacokinetic data expected in Q4 2026; an independent Data Monitoring Committee is overseeing the study Topline safety and pharmacokinetic data expected in Q4 2026; an independent Data Monitoring Committee is overseeing the study
Shares in Novo Nordisk (NYSE:NVO) held firm and edged higher in early trading on Thursday despite the US Food and Drug Administration approving a new once-daily weight-loss pill from rival Eli Lilly that sets up a fresh phase of competition in the lucrative obesity drug market. Novo stock rose 2.6% in opening deals on Thursday, suggesting investors and analysts had already priced in much of the competitive threat, with the Danish drugmaker's shares having fallen almost 50% over the past year as rival drugs emerged to challenge the dominance of its Ozempic and Wegovy franchises.
Romaine Mark
officer: Chief Operating Officer
2,065 SH @ $44.80
2026-03-25
Romaine Mark
officer: Chief Operating Officer
3,245 SH @ $48.10
2026-03-19
Romaine Mark
officer: Chief Operating Officer
2,020 SH @ $48.19
2026-03-20
Romaine Mark
officer: Chief Operating Officer
435 SH @ $47.31
2026-03-23
Romaine Mark
officer: Chief Operating Officer
1,323 SH @ $47.62
2026-03-12
Romaine Mark
officer: Chief Operating Officer
900 SH @ $47.50
2026-03-13
Romaine Mark
officer: Chief Operating Officer
3,376 SH @ $47.00
2026-03-16
Romaine Mark
officer: Chief Operating Officer
7,500 SH @ $47.39
2026-03-17